Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build

Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/hl7-eu/gravitate-health/ and changes regularly. See the Directory of published versions

Example DocumentReference: Example of additional support material - test match for alicia, HIV and biktarvy

Generated Narrative: DocumentReference

Resource DocumentReference "asm-alicia-example-2"

Profile: Additional Support Material Profile

relatedMedicalIssue: Human immunodeficiency virus infection (SNOMED CT#86406008)

identifier: http://example.org/3

version: 1.0

status: current

docStatus: final

​subject: MedicinalProductDefinition/mp2a9c4333cfd126f2e7b73ad3cafd6949

author: : hypertuny

description: Biktarvy, consisting of bictegravir, emtricitabine and tenofovir alafenamide, is a significant medication in the treatment of HIV and AIDS. This fixed-dose combination antiretroviral drug, approved for use in the United States in February 2018 and in the European Union in June 2018, is a combination therapy, often termed as highly active antiretroviral therapy. This therapy involves using two or more types of antiretroviral drugs. Each tablet of Biktarvy contains 50 milligrams bictegravir, 200 milligrams emtricitabine, and 25 milligrams tenofovir alafenamide, and is taken orally once daily.

content

Attachments

-ContentTypeLanguageUrlDuration
*audio/mpegenhttps://www.youtube.com/watch?v=HpndrPLs1Y8715